N@N

Liav Abraham Maintained (TEVA) at Strong Buy with Increased Target to $25 on, May 31st, 2018

Liav Abraham of Citigroup, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Strong Buy with Increased Target from $24 to $25 on, May 31st, 2018.

Liav has made no other calls on TEVA in the last 4 months.

There are 7 other peers that have a rating on TEVA. Out of the 7 peers that are also analyzing TEVA, 3 agree with Liav's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Douglas Tsao of "Barclays" Maintained at Hold with Increased Target to $20 on, Thursday, May 24th, 2018
• David Risinger of "Morgan Stanley" Maintained at Hold on, Monday, May 7th, 2018
• Gregg Gilbert of "Deutsche Bank" Maintained at Hold with Decreased Target to $18 on, Friday, February 9th, 2018

These are the ratings of the 4 analyists that currently disagree with Liav

---

• Vamil Divan of "Credit Suisse" Maintained at Buy with Increased Target to $23 on, Monday, February 12th, 2018
• Jason Gerberry of "B of A Securities" Maintained at Sell with Decreased Target to $16 on, Friday, February 9th, 2018
• Ami Fadia of "Leerink Swann" Maintained at Sell with Decreased Target to $16 on, Friday, February 9th, 2018
• David Amsellem of "Piper Sandler" Downgraded from Hold to Sell on, Friday, February 9th, 2018

Contributing Sources

---